24 completed, 13 recruiting, 8 active not recruiting, 8 unknown. 26 Phase 2, 12 Phase 1, 7 Not applicable, 6 Phase 3, 4 Phase 4.
Follow Locally Advanced Breast Cancer: new trials by email Literature Review of Locally Advanced Breast Cancer trials Research Report on Locally Advanced Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP Trastuzumab Rezetecan - Breast Cancer, HER2-positive Breast Cancer | Phase 4 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 59 | 2026-05-31 | 2026-05-15 |
| Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer Brief Acceptance and Commitment Therapy, Standard Counseling, Neoadjuvant Chemotherapy - Breast Cancer, Breast Neoplasm Female | Not applicable | Not yet recruiting | Universitas Airlangga | 54 | 2026-04-28 | 2026-05-06 |
| A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Inavolisib, Palbociclib, Fulvestrant - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Recruiting | Hoffmann-La Roche | 500 | 2026-01-21 | 2026-10-06 | |
| SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study SHR- A1811 - SHR-A1811, HER2-Postive Breast Cancer | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2025-12-20 | 2025-12-29 |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer Palazestrant, Letrozole-matching placebo, Ribociclib - Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Recruiting | Olema Pharmaceuticals, Inc. | 1000 | 2025-11-03 | 2026-09-23 |
| Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer Memantine, Placebo medication, Exercise Intervention - Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 90 | 2025-08-19 | 2026-05-06 |
| A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 240 | 2025-07-23 | 2026-10-02 |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer BNT323, BNT327 - Locally Advanced Breast Cancer, Unresectable Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 380 | 2025-04-23 | 2026-10-15 |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel - Locally Advanced Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Active not recruiting | BioNTech SE | 83 | 2024-08-26 | 2026-06-30 |
| A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer RPH-051, Docetaxel, Perjeta® - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Active not recruiting | R-Pharm | 246 | 2024-08-09 | 2026-07-14 |
| Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer neoadjuvant chemotherapy: anthracycline based chemotherapy and taxans before surgery - Locally Advanced Breast Cancer | Not yet recruiting | Assiut University | 45 | 2024-08-01 | 2024-07-12 | |
| Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer CEDM, CEDBT, Omnipaque 350mgI/mL Solution for Injection - Breast Cancer, Locally Advanced Breast Cancer | Early Phase 1 | Recruiting | Alison Stopeck | 30 | 2024-03-06 | 2026-01-15 |
| A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer Pembrolizumab, Cryoablation, Histotripsy - Metastatic Breast Cancer, Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2024-01-29 | 2026-09-14 |
| A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants Samuraciclib, Fulvestrant - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 2 | Completed | Carrick Therapeutics Limited | 60 | 2023-11-16 | 2025-12-26 |
| A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 49 | 2023-10-09 | 2026-03-23 |
| The Choice of Treatment Methods and Efficacy of LABC Modified radical mastectomy for breast cancer, neoadjuvant therapy, Systematic treatment - Locally Advanced Breast Cancer | Not applicable | Unknown | Peking Union Medical College Hospital | 50 | 2023-10-08 | 2023-10-12 |
| Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Trastuzumab deruxtecan - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 2 | Terminated | Spanish Breast Cancer Research Group | 2 | 2023-09-28 | 2026-04-02 |
| A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. FWD1802 - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Forward Pharmaceuticals Co., Ltd. | 99 | 2023-09-12 | 2026-02-10 |
| Breast Cancer Exercise Intervention Study Exercise Programme, Control - Early-stage Breast Cancer, Locally Advanced Breast Cancer | Not applicable | Recruiting | National Cancer Centre, Singapore | 2156 | 2023-07-01 | 2025-09-05 |
| Influence of Intermittent Fasting on Locally Advanced Breast Cancer Patients intermittent fasting - Locally Advanced Breast Cancer, Intermittent Fasting | Not applicable | Unknown | Menoufia University | 66 | 2023-06-01 | 2024-02-01 |
Showing 20 of 64. Sign in to see all of them.
Breast Neoplasms (51) · Triple Negative Breast Neoplasms (9) · Neoplasm Metastasis (3) · Neoplasms (3) · Inflammatory Breast Neoplasms (2) · Biliary Tract Neoplasms (1) · COVID-19 (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Cognitive Dysfunction (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Hemangiosarcoma (1) · Intermittent Fasting (1)
Breast Diseases (52) · Neoplasms by Site (52) · Skin Diseases (52) · Skin and Connective Tissue Diseases (52) · Neoplasms (50) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Behavior (5) · Neoplastic Processes (4) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2)
Letrozole (7) · Paclitaxel (7) · Fulvestrant (6) · pertuzumab (6) · Carboplatin (5) · Neoadjuvant Therapy (5) · Trastuzumab (5) · palbociclib (5) · Ado-Trastuzumab Emtansine (3) · Cyclophosphamide (3) · Docetaxel (3) · abemaciclib (3) · pembrolizumab (3) · pyrotinib (3) · ribociclib (3)
Hoffmann-La Roche (3) · Alison Stopeck (2) · BioNTech SE (2) · Carrick Therapeutics Limited (2) · Hospices Civils de Lyon (2) · Memorial Sloan Kettering Cancer Center (2) · Olema Pharmaceuticals, Inc. (2) · RenJi Hospital (2) · Rhizen Pharmaceuticals SA (2) · Abramson Cancer Center at Penn Medicine (1) · Antonio Giordano, MD (1) · Assiut University (1) · AstraZeneca (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Cancer Trials Ireland (1)
United States (23) · China (11) · Spain (9) · Canada (8) · United Kingdom (7) · France (6) · Australia (4) · South Korea (4) · Turkey (Türkiye) (4) · Belgium (3) · Brazil (3) · Germany (3) · Hungary (3) · Italy (3) · Mexico (3)
Alison Stopeck, MD (2) · Jinsong Lu (2) · Aarti Bhardwaj, MD (1) · Alicia Okines (1) · Andrea Barrio, MD (1) · Antonio C Giordano, MD, PhD (1) · Asdi Wihandono, MD, Surgical Oncologist (1) · Binghe Xu, Dr. (1) · Bostjan Seruga, MD (1) · Brian Yaremko, MD (1)
PMID 17183730, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 25248945, PMID 26793976, PMID 27094900, PMID 27406346, PMID 27406347, PMID 28439738, PMID 28851423, PMID 30098917, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 32715776, PMID 34529000, PMID 34741021, PMID 35235412, PMID 35623341, PMID 35993306, PMID 36069821, PMID 36456573, PMID 37029329, PMID 37325931, PMID 37505107, PMID 38086377, PMID 38180338, PMID 38362377, PMID 38745646, PMID 38979716, PMID 39039516, PMID 39046616, PMID 39073142, PMID 39158353, PMID 39277671, PMID 39277672, PMID 39613746, PMID 39625569, PMID 40526879, PMID 40551254, PMID 40639409, PMID 40679371, PMID 40777112, PMID 40970572, PMID 41879562, PMID 42530945, PMID 42545411
2023 (4), 2016 (2), 2019 (1), K23AG086604 (1)